Company Profile

Omeros Corporation
Profile last edited on: 11/13/2023      CAGE: 357C4      UEI: HM97JEC22LP2

Business Identifier: Small-molecule and protein therapeutics for variety of indications
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

201 Elliott Avenue West
Seattle, WA 98119
   (206) 676-5000
Location: Multiple
Congr. District: 07
County: King

Public Profile

Omeros Corporation is a clinical-stage biopharmaceutical company organized around inflammation and disorders of the central nervous system. The firm's product candidates are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company's lead PharmacoSurgery product candidate, OMS103HP, is in Phase III clinical program for evaluating OMS103HPs safety and ability to improve postoperative joint function and reduce pain following arthroscopic anterior cruciate ligament; and to reduce pain and improve postoperative joint function following arthroscopic meniscectomy surgery. Its PharmacoSurgery product candidates also include OMS302, which completed its Phase I/II clinical trial for use during ophthalmological procedures; and OMS201, which is in Phase I/II clinical trial for use during urological surgery. The company also engages in developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPAR?) agonists for the treatment and prevention of addiction to substances of abuse. Its pipeline of preclinical product development programs include MASP-2 program for developing proprietary mannan-binding lectin-associated serine protease-2 antibody therapies to treat disorders caused by complement-activated inflammation; PDE10 program for developing proprietary compounds to treat schizophrenia and other psychotic disorders; PDE7 program for developing proprietary compounds to treat movement disorders; and GPCR program for the de-orphanization of orphan G protein-coupled receptors

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $1,148,909
Project Title: Development Of Novel Analgesics Targeting A Brain Gpcr
2013 2 NIH $697,020
Project Title: Monoclonal Antibodies For Orphan Gpcrs In The Cns
2012 1 NIH $193,002
Project Title: Masp-2 Antibodies For Diabetic Neuropathy
2011 2 NIH $802,812
Project Title: MASP-2 Therapy for Macular Degeneration
2010 1 NIH $198,383
Project Title: Development Of Masp-2 Moabs For The Treatment Of Diabetic Nephropathy

Key People / Management

  Gregory A Demopulos -- Founder, Chairman & CEO

  John Bergmann

  Neil S Cutshall

  Thomas A Dudler

  Timothy M Duffy -- Vice president, business development

  Kenneth Ferguson -- Vice President, Development

  George A Gaitanaris -- Vice President, Science

  Wayne R Gombotz -- VP, Pharmaceutical Operations

  Alexander Gragerov

  Pat Gray

  Emma E Moore

  Pamela Pierce Palmer -- Founder

  Paul J Simpson